NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Qayyum R, Wilson LM, Bolen S, et al. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Sep. (Comparative Effectiveness Reviews, No. 14.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

References

1.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837–53. [PubMed: 9742976]
2.
Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: U.S.: Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.
3.
Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174–83. [PubMed: 15647580]
4.
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289(17):2254–64. [PubMed: 12734137]
5.
Marrero DG. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. Clin Cornerstone. 2007;8(2):33–40. discussion 41–3. [PubMed: 18357954]
6.
Hendra TJ, Taylor CD. A randomised trial of insulin on well-being and carer strain in elderly type 2 diabetic subjects. J Diabetes Complications. 2004;18(3):148–54. [PubMed: 15145325]
7.
Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 2005;27(8):1113–25. [PubMed: 16199240]
8.
Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006;66(1):31–49. [PubMed: 16398567]
9.
Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med. 2002;19(5):393–9. [PubMed: 12027927]
10.
Roach P, Trautmann M, Arora V, Sun B, Anderson JH Jr. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clin Ther. 1999;21(3):523–34. [PubMed: 10321421]
11.
McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther. 2002;24(4):530–9. [PubMed: 12017398]
12.
Herz M, Arora V, Campaigne BN, Scholtz HE, Potgieter MA, Mollentze W. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. S Afr Med J. 2003;93(3):219–23. [PubMed: 12768948]
13.
Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(6):446–54. [PubMed: 14617231]
14.
Malone JK, Yang H, Woodworth JR. et al. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab. 2000;26(6):481–7. [PubMed: 11173719]
15.
Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17(6):307–13. [PubMed: 14583174]
16.
Novo Nordisk. NovoLog Mix 70/30 Package Insert. [Web Page]. Available at http://www​.novologmix70-30​.com/NovoLogMix7030_PI.pdf. (Accessed 2 February 2008).
17.
Eli Lilly and Company. Humalog Mix75/25 Patient Information. [Web Page]. Available at http://www​.humalog.com/index.jsp. (Accessed 2 February 2008).
18.
Eli Lilly and Company. Humalog Mix50/50 Patient Information. [Web Page]. Available at http://www​.humalog.com/index.jsp. (Accessed 2 February 2008).
19.
Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350(9072):185–6. [PubMed: 9250191]
20.
Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. [PubMed: 8721797]
21.
Wells, GA, Shea, B, O'Connel, D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Web Page]. (Accessed 20 September 2007).
22.
Guide for Conducting Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality, 2007.
23.
Valdez R, Yoon PW, Liu T, Khoury MJ. Family history and prevalence of diabetes in the US population: 6-year results from the National Health and Nutrition Examination Survey (NHANES, 1999 2004). Diabetes 2007. [PubMed: 17666469]
24.
Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45(7):769–73. [PubMed: 1619456]
25.
Robertson C, Idris NR, Boyle P. Beyond classical meta-analysis: can inadequately reported studies be included? Drug Discov Today. 2004;9(21):924–31. [PubMed: 15501727]
26.
Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006;295(14):1688–97. [PubMed: 16609091]
27.
Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet. 1991;338(8775):1127–30. [PubMed: 1682553]
28.
Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 1991;10(11):1665–77. [PubMed: 1792461]
29.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101. [PubMed: 7786990]
30.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. [PMC free article: PMC2127453] [PubMed: 9310563]
31.
Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63. [PubMed: 10877304]
32.
Holman RR, Thorne KI, Farmer AJ. et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. N Engl J Med. 2007;357(17):1716–30. [PubMed: 17890232]
33.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48. [PubMed: 13655060]
34.
Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 1986;124(5):719–23. [PubMed: 3766505]
35.
Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53–77. [PubMed: 16596572]
36.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–71. [PubMed: 2858114]
37.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
38.
Atkins D, Best D, Briss PA. et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. [PMC free article: PMC428525] [PubMed: 15205295]
39.
Raskin P, Allen E, Hollander P. et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–5. [PubMed: 15677776]
40.
Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, Garber AJ. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med. 2007;18(1):56–62. [PubMed: 17223044]
41.
Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes. 2007;5:8. [PMC free article: PMC1802740] [PubMed: 17286868]
42.
Roach, Koledova E, Metcalfe S, Hultman C, Milicevic Z. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. Clin Ther. 2001;23(10):1732–44. [PubMed: 11726007]
43.
Tirgoviste CI, Strachinariu R, Farcasiu E, Milicevic Z, Teodorescu G. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Rom J Intern Med. 2003;41(2):153–62. [PubMed: 15526500]
44.
Malone JK, Woodworth JR, Arora V. et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther. 2000;22(2):222–30. [PubMed: 10743981]
45.
Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004;15(8):496–502. [PubMed: 15668084]
46.
Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(5):724–32. [PubMed: 17593237]
47.
Tamemoto H, Ikoma A, Saitoh T, Ishikawa SE, Kawakami M. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes. Diabetes Technol Ther. 2007;9(3):246–53. [PubMed: 17561795]
48.
McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30(5):1044–8. [PubMed: 17277042]
49.
Nauck MA, Duran S, Kim D. et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259–67. [PubMed: 17160407]
50.
Kann PH, Wascher T, Zackova V. et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114(9):527–32. [PubMed: 17115351]
51.
Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab. 2006;8(1):39–48. [PubMed: 16367881]
52.
Joshi SR, Kalra S, Badgandi M, Rao YS, Chawla M. Designer insulins regimens in clinical practice—pilot multicenter Indian study. J Assoc Physicians India. 2005;53:775–9. [PubMed: 16334621]
53.
Abrahamian H, Ludvik B, Schernthaner G. et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). Horm Metab Res. 2005;37(11):684–9. [PubMed: 16308837]
54.
Raz I, Stranks S, Filipczak R. et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther. 2005;27(9):1432–43. [PubMed: 16291416]
55.
Niskanen L, Jensen LE, Rastam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26(4):531–40. [PubMed: 15189750]
56.
Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. Diabet Med. 2004;21(5):500–1. [PubMed: 15089801]
57.
Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Harman-Boehm I. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther. 2003;25(12):3109–23. [PubMed: 14749149]
58.
Hermansen K, Colombo M, Storgaard H, OStergaard A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 2002;25(5):883–8. [PubMed: 11978685]
59.
Ushakova O, Sokolovskaya V, Morozova A. et al. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. Clin Ther. 2007;29(11):2374–84. [PubMed: 18158078]
60.
Raskin P, Matfin G, Schwartz SL et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). Diabetes Obes Metab 2007. [PubMed: 17941873]
61.
Hirao K, Arai K, Yamauchi M, Takagi H, Kobayashi M. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract. 2008;79(1):171–6. [PubMed: 17919762]
62.
Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther. 2006;28(10):1649–57. [PubMed: 17157120]
63.
Roach P, Malone JK. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. Diabet Med. 2006;23(7):743–9. [PubMed: 16842478]
64.
Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab. 2006;8(4):448–55. [PubMed: 16776752]
65.
Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26(12):2034–44. [PubMed: 15823767]
66.
Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med. 2005;22(4):374–81. [PubMed: 15787659]
67.
Coscelli C, Iacobellis G, Calderini C. et al. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol. 2003;40(4):187–92. [PubMed: 14740279]
68.
Malone JK, Beattie SD, Campaigne BN, Johnson PA, Howard AS, Milicevic Z. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract. 2003;62(3):187–95. [PubMed: 14625133]
69.
Roach P, Arora V, Campaigne BN, Mattoo V, Rangwala S. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab. 2003;5(5):311–6. [PubMed: 12940868]
70.
Mattoo V, Milicevic Z, Malone JK. et al. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract. 2003;59(2):137–43. [PubMed: 12560163]
71.
Herz M, Profozic V, Arora V. et al. Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes. Curr Med Res Opin. 2002;18(4):188–93. [PubMed: 12201618]
72.
Herz M, Sun B, Milicevic Z. et al. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther. 2002;24(1):73–86. [PubMed: 11833837]
73.
Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care. 1999;22(8):1258–61. [PubMed: 10480767]
74.
Cox DJ, McCall A, Kovatchev B, Sarwat S, Ilag LL, Tan MH. Effects of blood glucose rate of changes on perceived mood and cognitive symptoms in insulin-treated type 2 diabetes. Diabetes Care. 2007;30(8):2001–2. [PubMed: 17473060]
75.
Sun P, Wang R, Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin. 2007;23(12):3017–23. [PubMed: 17961295]
76.
Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications. 2006;20(3):145–52. [PubMed: 16632233]
77.
Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res. 2004;36(3):188–93. [PubMed: 15057674]
78.
Yamada S, Watanabe M, Kitaoka A. et al. Switching from premixed human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life. Intern Med. 2007;46(18):1513–7. [PubMed: 17878636]
79.
Robbins DC, Beisswenger PJ, Ceriello A. et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2007;29(11):2349–64. [PubMed: 18158076]
80.
Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31(1):20–5. [PubMed: 17934150]
81.
Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836–48. [PubMed: 14693308]
82.
Eli Lilly. Trial 4957 Pilot Study Investigating the Effects of Insulin Lispro Low Mixture Compared with Insulin Glargine on Perceived Mood Symptoms in Patients with Type 2 Diabetes Mellitus. 2006.
83.
Ligthelm RJ, Mouritzen U, Lynggaard H. et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006;114(9):511–9. [PubMed: 17115349]
84.
Takeda Pharmaceuticals North America, I. ACTOS, A Type 2 Diabetes Treatment: Prescribing Information [Web Page]. September 2007; Available at http://www​.actos.com​/actos/prescribinginfo.aspx. (Accessed 1 May 2008).
85.
GlaxoSmithKline. AVANDIA (rosiglitazone maleate) Tablets. Highlights of Prescribing Information [Web Page]. March 2008; Available at http://us​.gsk.com/products​/assets/us_avandia.pdf. (Accessed 1 May 2008).
86.
Center for Drug Evaluation and Research. Medical Review(s). Application Number: 21-017, 21-018 [Web Page]. Available at http://www.fda.gov/cder/foi/nda/99/21017_Humalog_medr.pdf. (Accessed 30 August 2007).
87.
Center for Drug Evaluation and Research. Medical Review(s). Approval Package for: NovoLog Mix 70-30. Application Number: 21-172 [Web Page]. (Accessed 30 August 2007).
88.
European Medicine Agency. European Public Assessment Report for NovoRapid. Scientific Discussion. [Web Page]. Available at http://www​.emea.europa​.eu/humandocs/PDFs​/EPAR/Novorapid/272799en6.pdf. (Accessed 30 August 2007).
89.
Eli Lilly and Company. Summary ID #4050. Clinical Study Summary: Study F3Z-MC-IOND. Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin [Web Page]. Available at http://www​.clinicalstudyresults​.org/documents​/company-study_1045_0.pdf. (Accessed 30 August 2007).
90.
Eli Lilly and Company. Summary ID #5881. Clinical Study Summary: Study F3Z-US-IONW. Comparison of Intensive Mixture Therapy vs. Basal Insulin Therapy in Patients with Type 2 Diabetes Receiving Oral Antidiabetes Agents [Web Page]. Available at http://www​.clinicalstudyresults​.org/documents​/company-study_1048_0.pdf.
91.
Eli Lilly and Company. Summary ID #4011. Clinical Study Summary: Study F3Z-MC-IOMX. Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabets on NPH Alone or Combination Therapy of Insulin and Oral Agents [Web Page]. Available at http://www​.clinicalstudyresults​.org/documents​/company-study_2418_0.pdf. (Accessed 30 August 2007).
92.
Novo Nordisk. Biphasic insulin aspart. Trial ID: BIAsp-1579. Integrated Clinical Trial Report. Report Body and Synopsis [Web Page]. 29 June 2006; Available at http://www​.novonordisk-trials​.com/website​/pdf/registry/bin_20070903-125523-991​.pdf. (Accessed 30 April 2008).
93.
Novo Nordisk. Biphasic insulin aspart 30. Trial ID: BIAsp-1594. Clinical Trial Report. Report Synopsis [Web Page]. 20 July 2007; Available at http://www​.novonordisk-trials​.com/website​/pdf/registry/bin_20071204-125712-724​.pdf. (Accessed 30 April 2008).
94.
Clinical Practice Recommendations 2005. Diabetes Care 2005; 28 Suppl 1:S1–79. [PubMed: 15618109]
95.
The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management—2000 update. Endocr Pract 2000; 6(1):43–84. [PubMed: 11428359]
96.
Abrahamson MJ. Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Arch Intern Med. 2004;164(5):486–91. [PubMed: 15006824]
97.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–5. [PubMed: 12610053]
98.
Woerle HJ, Neumann C, Zschau S. et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–5. [PubMed: 17240473]
99.
Standards of medical care in diabetes—2008. Diabetes Care 2008; 31 Suppl 1:S12–54. [PubMed: 18165335]
100.
Monnier L, Colette C, Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12(Suppl 1):42–6. [PubMed: 16627379]
101.
White JR Jr. Insulin glargine clinical trials. Clin Ther. 2004;26(7):1179–81. discussion 1182–3. [PubMed: 15336483]
102.
Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care. 1997;20(2):163–9. [PubMed: 9118765]
103.
Orencia AJ, Daviglus ML, Dyer AR, Walsh M, Greenland P, Stamler J. One-hour postload plasma glucose and risks of fatal coronary heart disease and stroke among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry (CHA) Study. J Clin Epidemiol. 1997;50(12):1369–76. [PubMed: 9449940]
104.
de Vegt F, Dekker JM, Ruhe HG. et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42(8):926–31. [PubMed: 10491751]
105.
Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation. 1995;91(10):2591–5. [PubMed: 7743621]
106.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–9. [PubMed: 10860187]
107.
Wake N, Hisashige A, Katayama T. et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract. 2000;48(3):201–10. [PubMed: 10802159]
108.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–94. [PubMed: 12876091]
109.
Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214–9. [PubMed: 15197140]
110.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):854–65. [PubMed: 9742977]
111.
Bethel MA, Feinglos MN. Insulin analogues: new therapies for type 2 diabetes mellitus. Curr Diab Rep. 2002;2(5):403–8. [PubMed: 12643165]
112.
Schellhase KG, Koepsell TD, Weiss NS. Glycemic control and the risk of multiple microvascular diabetic complications. Fam Med. 2005;37(2):125–30. [PubMed: 15690253]
113.
Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127(9):788–95. [PubMed: 9382399]
114.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837–53. [PubMed: 9742976]
115.
The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44(8):968–83. [PubMed: 7622004]
116.
Selvin E, Marinopoulos S, Berkenblit G. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–31. [PubMed: 15381515]
117.
Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–6. [PubMed: 16239637]
118.
Kahn SE, Haffner SM, Heise MA. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–43. [PubMed: 17145742]
119.
National Heart Lung and Blood Institute. ACCORD, Questions and Answers, NHLBI [Web Page]. 13 February 2008; Available at http://www​.nhlbi.nih​.gov/health/prof/heart/other/accord/q_a​.htm. (Accessed 3 May 2008).
120.
sanofi-aventis. Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects with With Diabetes Mellitus (Type 1 or Type 2) [Web Page]. 1 May 2008; Available at http://www​.clinicaltrials​.gov/ct2/show/NCT00135941. (Accessed 2 May 2008).
121.
sanofi-aventis. Insulin Glargine “All to Target” Trial [Web Page]. 1 May 2008; Available at http://www​.clinicaltrials​.gov/ct2/show/NCT00384085. (Accessed 2 May 2008).
122.
Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45(7):937–48. [PubMed: 12136392]
123.
Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther. 2005;27(Suppl B):S75–88. [PubMed: 16519039]
124.
Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127–42. [PubMed: 18035865]
125.
Gough SC, Tibaldi J. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review. Clin Drug Investig. 2007;27(5):299–324. [PubMed: 17451279]
126.
Sanofi-aventis Groupe. GINGER: Insulin Glulisine in Diabetes Mellitus, Type 2 [Web Page]. 1 May 2008; Available at http://www​.clinicaltrials​.gov/ct2/show/NCT00174668. (Accessed 2 May 2008).
Copyright Notice
Bookshelf ID: NBK43182
Contents